ERBB2 and small cell lung carcinoma: Recent advancements in management of metastatic UC with antibody‐drug conjugates (ADC), targeting Nectin‐4, and human epidermal growth factor receptor 2 (HER2) [13, 14, 15], leave an unanswered question of the best strategy to treat relapsed SCNEC with these agents versus other agents that have activity in SCLC [16].